The American Cancer Society estimated that in 2004, breast or colorectal cancer would strike over 350,000 Americans and close to 100,000 people would die from these diseases. The National Surgical Adjuvant Breast and Bowel Project(NSABP) is a multi-center clinical cooperative trials group with nearly 200 member institutions located throughout the US, Canada and Puerto Rico. The primary research objective of the NSABP is to conduct therapeutic research designed to improve the survival and the quality of life for persons with breast or colorectal cancer. This goal is achieved through the conduct of definitive phase III trials and the developmental efforts that lead to them. In calendar years 2002 and 2003, the NSABP entered 10,270 breast cancer patients and 962 colorectal cancer patients into adjuvant therapy trials. According to NCI data, this represents 64% of the breast cancer patients and 78% of the colorectal cancer patients entering NCI sponsored phase III cooperative group adjuvant breast or colorectal adjuvant trials. The NSABP integrates key behavior and health outcomes into its phase III trials to provide added value to the traditional endpoints of disease-free and overall survival. The NSABP also conducts correlative laboratory research in conjunction with its clinical trials designed to improve methods of assessing prognosis and predicting response to treatment with the aim of optimizing therapy for individual patients. In the proposed project period our aim will be to continue to improve breast and colorectal cancer therapies through the development and conduct of well-designed Phase III adjuvant therapy trials which will be carried out at our extensive network of affiliated members throughout North America.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Nsabp Foundation, Inc.
United States
Zip Code
Ribi, Karin; Luo, Weixiu; Bernhard, Jürg et al. (2016) Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol 34:1601-10
Cheung, Winson Y; Renfro, Lindsay A; Kerr, David et al. (2016) Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. J Clin Oncol 34:1182-9
Regan, Meredith M; Francis, Prudence A; Pagani, Olivia et al. (2016) Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol 34:2221-31
Wolmark, Norman; Mamounas, Eleftherios P; Baehner, Frederick L et al. (2016) Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/Nati J Clin Oncol 34:2350-8
Johansson, Harriet; Gray, Kathryn P; Pagani, Olivia et al. (2016) Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Res 18:110
Chapman, Judith-Anne W; Costantino, Joseph P; Dong, Bin et al. (2015) Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. Breast Cancer Res Treat 153:353-60
Wickerham, D Lawrence; Vogel, Victor G (2015) Breast cancer chemoprevention: the saga of underuse continues. J Natl Cancer Inst 107:399
Vachon, Celine M; Schaid, Daniel J; Ingle, James N et al. (2015) A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. Breast Cancer Res Treat 149:517-23
Valdivieso, Manuel; Corn, Benjamin W; Dancey, Janet E et al. (2015) The Globalization of Cooperative Groups. Semin Oncol 42:693-712
Pogue-Geile, Katherine L; Song, Nan; Jeong, Jong-Hyeon et al. (2015) Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol 33:1340-7

Showing the most recent 10 out of 253 publications